Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 8.36
APPY's Cash to Debt is ranked higher than
58% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. APPY: 8.36 )
Ranked among companies with meaningful Cash to Debt only.
APPY' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 3.37 Max: N/A
Current: 8.36
Equity to Asset 0.82
APPY's Equity to Asset is ranked higher than
79% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. APPY: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
APPY' s Equity to Asset Range Over the Past 10 Years
Min: -0.05  Med: 0.62 Max: 0.85
Current: 0.82
-0.05
0.85
F-Score: 7
Z-Score: -5.24
M-Score: -2.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3041.42
APPY's Operating margin (%) is ranked lower than
93% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. APPY: -3041.42 )
Ranked among companies with meaningful Operating margin (%) only.
APPY' s Operating margin (%) Range Over the Past 10 Years
Min: -14454.84  Med: -3477.99 Max: -221.16
Current: -3041.42
-14454.84
-221.16
Net-margin (%) -3049.63
APPY's Net-margin (%) is ranked lower than
93% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. APPY: -3049.63 )
Ranked among companies with meaningful Net-margin (%) only.
APPY' s Net-margin (%) Range Over the Past 10 Years
Min: -14858.06  Med: -3330.13 Max: -245.81
Current: -3049.63
-14858.06
-245.81
ROE (%) -36.91
APPY's ROE (%) is ranked lower than
69% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. APPY: -36.91 )
Ranked among companies with meaningful ROE (%) only.
APPY' s ROE (%) Range Over the Past 10 Years
Min: -135.53  Med: -101.94 Max: -40.1
Current: -36.91
-135.53
-40.1
ROA (%) -30.65
APPY's ROA (%) is ranked lower than
69% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. APPY: -30.65 )
Ranked among companies with meaningful ROA (%) only.
APPY' s ROA (%) Range Over the Past 10 Years
Min: -78.91  Med: -56.51 Max: -30.69
Current: -30.65
-78.91
-30.69
ROC (Joel Greenblatt) (%) -391.24
APPY's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. APPY: -391.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
APPY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -505.6  Med: -339.77 Max: -53
Current: -391.24
-505.6
-53
Revenue Growth (3Y)(%) -63.80
APPY's Revenue Growth (3Y)(%) is ranked lower than
95% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. APPY: -63.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
APPY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.8  Med: -30.20 Max: -2.3
Current: -63.8
-68.8
-2.3
EBITDA Growth (3Y)(%) -63.40
APPY's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. APPY: -63.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
APPY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.4  Med: 7.50 Max: 43.8
Current: -63.4
-63.4
43.8
EPS Growth (3Y)(%) -63.70
APPY's EPS Growth (3Y)(%) is ranked lower than
95% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. APPY: -63.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
APPY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.7  Med: 1.45 Max: 37.8
Current: -63.7
-63.7
37.8
» APPY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with APPY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.40
APPY's P/B is ranked higher than
97% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.84 vs. APPY: 0.40 )
Ranked among companies with meaningful P/B only.
APPY' s P/B Range Over the Past 10 Years
Min: 0.26  Med: 3.47 Max: 38.96
Current: 0.4
0.26
38.96
EV-to-EBIT 1.13
APPY's EV-to-EBIT is ranked higher than
93% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. APPY: 1.13 )
Ranked among companies with meaningful EV-to-EBIT only.
APPY' s EV-to-EBIT Range Over the Past 10 Years
Min: -81.4  Med: -2.00 Max: 1.13
Current: 1.13
-81.4
1.13
EV-to-EBITDA 1.15
APPY's EV-to-EBITDA is ranked higher than
93% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.38 vs. APPY: 1.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
APPY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -85.9  Med: -2.10 Max: 1.15
Current: 1.15
-85.9
1.15
Current Ratio 17.36
APPY's Current Ratio is ranked higher than
97% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. APPY: 17.36 )
Ranked among companies with meaningful Current Ratio only.
APPY' s Current Ratio Range Over the Past 10 Years
Min: 0.31  Med: 5.25 Max: 21.99
Current: 17.36
0.31
21.99
Quick Ratio 17.36
APPY's Quick Ratio is ranked higher than
98% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. APPY: 17.36 )
Ranked among companies with meaningful Quick Ratio only.
APPY' s Quick Ratio Range Over the Past 10 Years
Min: 0.08  Med: 4.50 Max: 21.99
Current: 17.36
0.08
21.99
Days Payable 1.00
APPY's Days Payable is ranked lower than
98% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. APPY: 1.00 )
Ranked among companies with meaningful Days Payable only.
APPY' s Days Payable Range Over the Past 10 Years
Min: 180.81  Med: 1101.87 Max: 224110
Current: 1
180.81
224110

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.52
APPY's Price/Net Cash is ranked higher than
98% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.08 vs. APPY: 0.52 )
Ranked among companies with meaningful Price/Net Cash only.
APPY' s Price/Net Cash Range Over the Past 10 Years
Min: 0.65  Med: 5.65 Max: 51.79
Current: 0.52
0.65
51.79
Price/Net Current Asset Value 0.51
APPY's Price/Net Current Asset Value is ranked higher than
98% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.80 vs. APPY: 0.51 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
APPY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.63  Med: 5.13 Max: 45.23
Current: 0.51
0.63
45.23
Price/Tangible Book 0.45
APPY's Price/Tangible Book is ranked higher than
96% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. APPY: 0.45 )
Ranked among companies with meaningful Price/Tangible Book only.
APPY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.55  Med: 5.79 Max: 97.5
Current: 0.45
0.55
97.5
Earnings Yield (Greenblatt) (%) 88.35
APPY's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. APPY: 88.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
APPY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 88.35  Med: 379.60 Max: 1400.6
Current: 88.35
88.35
1400.6

More Statistics

Revenue(Mil) $0
EPS $ -0.27
Beta2.08
Short Percentage of Float1.96%
52-Week Range $0.21 - 0.70
Shares Outstanding(Mil)30.99

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 1 3
EPS($) -0.37 -0.41
EPS without NRI($) -0.37 -0.41

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AP4B.Germany,
Venaxis Inc was organized on July 24, 2000, as a Colorado corporation. In December 2012, the Company's name was changed to Venaxis, Inc., from AspenBio Pharma, Inc. The Company is engaged in development and commercialization of products that address unmet diagnostic and therapeutic needs. The Company's product candidate, APPY1, is designed to be a novel blood-based diagnostic test that, if successfully cleared to be marketed by the United States Food and Drug Administration (FDA), will aid, through the test's negative predictive value, in the evaluation of low risk patients initially suspected of having acute appendicitis, thereby helping address the difficult challenge of triaging possible acute appendicitis patients in the hospital emergency department or urgent care settings. The APPY1, is intended to be used by emergency department and urgent care physicians to aid them in the evaluation of possible appendicitis in children, adolescent and young adult patients (ages 2 - 20) that present with abdominal pain. The FDA has regulatory marketing authority in the United States over its APPY1 products. The Company operates under ISO9001-4385 standards for cGMP manufacturing of medical devices. The Company is subject to various environmental laws pertaining to the disposal of hazardous medical waste. It contracts for disposal of hazardous waste with a licensed disposal facility.
» More Articles for APPY

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Nov 05 2010 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Aug 05 2010 
Weekly CFO Buys Highlight: AspenBio Pharma, Solarwinds, Affymetrix, Cascade Financial Corp., Bank of Jul 31 2010 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Nov 05 2009 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Aug 07 2009 
AspenBio Pharma Inc. (APPY) CEO Daryl Faulkner buys 10,000 Shares May 21 2009 
AspenBio Pharma Inc. (APPY) COO & Chief Medical Officer Robert Frederick Caspari buys 3,200 Shares May 19 2009 

More From Other Websites
VENAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jan 27 2016
Colorado medical technology companies to merge Jan 26 2016
Venaxis Announces Transaction with Strand Life Sciences Jan 26 2016
VENAXIS, INC. Financials Dec 08 2015
Venaxis, Inc. Earnings Q3, 2015 Nov 30 2015
VENAXIS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2015
Venaxis, Inc. – Value Analysis (NASDAQ:APPY) : October 23, 2015 Oct 23 2015
VENAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Oct 21 2015
Venaxis, Inc. Earnings Q2, 2015 Oct 01 2015
VENAXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Sep 03 2015
VENAXIS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2015
VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 24 2015
Venaxis Business Update Jun 22 2015
VENAXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 12 2015
VENAXIS, INC. Files SEC form 10-Q, Quarterly Report May 12 2015
VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 07 2015
Venaxis to Provide Business Update Apr 06 2015
3 Stocks Under $10 Triggering Breakout Trades Apr 02 2015
VENAXIS, INC. Files SEC form 10-K, Annual Report Mar 30 2015
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action... Mar 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK